LJPc Competitors

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,500 people across 46 countries.

As the immunology innovation company, argenx develops first-in-class medicines that change the course of disease and set a new direction for patients waiting for a breakthrough. Entrepreneurial Science shapes how we work: challenging conventions, pursuing bold pathways over conventional ones through the power of co-creation, and working alongside scientists, physicians and academic researchers with shared ambition — changing outcomes. Our purpose is to move immunology science faster than thought possible for patients who need progress now.

Lengo Therapeutics has been acquired by Blueprint Medicines. Follow @Blueprint Medicines and visit the Blueprint Medicines website to learn more: https://www.blueprintmedicines.com/